Zykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK). In most ALK-positive non-small cell lung cancer (NSCLC) cases, inversions in chromosome 2 cause ALK to fuse to echinoderm microtubule-associated protein-like 4.
This activates the ALK kinase domain and downstream signaling pathways responsible for excess cancer cell proliferation. ALK gene rearrangements are found more commonly in younger, non-smoking NSCLC patients and make up 3-5% of all NSCLC cases.
Key Topics Covered
- Drug Overview
- Product Profiles
- Zykadia : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
Figure 1: The authors drug assessment summary for Zykadia in non-small cell lung cancer
Figure 2: The authors drug assessment summary for ensartinib in non-small cell lung cancer
LIST OF TABLES
Table 1: Zykadia drug profile
Table 2: Zykadia pivotal trial data in non-small cell lung cancer
Table 3: Zykadia sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 4: Zykadia patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
For more information about this report visit https://www.researchandmarkets.com/r/i2090h